We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Nanoparticles and Faraday Rotation Allow Faster Diagnoses

By LabMedica International staff writers
Posted on 02 Feb 2017
Magnetic nanoparticles that are coated with an antibody, then aligned in formation within a magnetic field and tallied under laser optics could lead to speedy diagnoses for infectious diseases.

A clinically relevant magneto-optical technique, frequency-domain Faraday rotation spectroscopy (fd-FRS) for characterizing proteins using antibody-functionalized magnetic nanoparticles (MNPs) has been developed.

Bioengineers at the University of Central Florida developed the technique that distinguishes between the Faraday rotation of the solvent, iron oxide core, and functionalization layers of polyethylene glycol polymers (spacer) and model antibody–antigen complexes (anti-BSA/BSA, bovine serum albumin). More...
The technique was combined with predictive analyte binding models quantifies (within an order of magnitude) the number of active binding sites on functionalized MNPs.

The scientists observed a detection sensitivity of ≈10 pg mL−1 and broad detection range of 10 pg mL−1 ≲ cBSA ≲ 100 µg mL−1. Comparative enzyme-linked immunosorbent assay (ELISA) studies are conducted, reproducing the manufacturer advertised BSA ELISA detection limits from 1 ng mL−1 ≲ cBSA ≲ 500 ng mL−1. In addition to the increased sensitivity, broader detection range, and similar specificity, fd-FRS can be conducted in less than 30 minutes, compared to four hours or so with an ELISA.

The authors say that other antigens and their unique antibodies could be substituted for the BSA protein used in the study, allowing medical tests for a wide array of infectious diseases. The proof of concept shows the method could be used to produce biochemical immunology test results in as little as 15 minutes, compared to several hours for ELISA, or enzyme-linked immunosorbent assay, which is currently a standard approach for biomolecule detection. The discovery, if commercialized, could lead to faster test results for human immunodeficiency virus (HIV), Lyme disease, syphilis, rotavirus and other infectious conditions. Shawn A. Putnam, PhD, an assistant professor and a co-author of the study said, “I see no reason why a variation of this technique couldn't be in every hospital throughout the world.” The study was published on January 16, 2017, in the journal Small.


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.